Last reviewed · How we verify

Neuropathic pain associated with spinal cord injury — Treatment Landscape & Competitive Intelligence

Neuropathic pain associated with spinal cord injury (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neuropathic pain associated with spinal cord injury, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lyrica Pregabalin Pfizer Inc. Anticonvulsant, analgesic alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)
Neurontin Gabapentin Pfizer Inc. Antiepileptic/Analgesic α2δ subunit of voltage-activated calcium channels

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 2 drugs in Neuropathic pain associated with spinal cord injury

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neuropathic pain associated with spinal cord injury:

Cite this brief

Drug Landscape (2026). Neuropathic pain associated with spinal cord injury — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neuropathic-pain-associated-with-spinal-cord-injury. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing